This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here.
Early-stage biotech companies can make some big promises to their investors — lofty claims that they’re creating the first drug to treat a disease or first to use a new kind of biology or chemistry. And in return for those promises, investors hand over millions of dollars.
About the Author Reprints
